Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Qilian International Holding Group Limited (BGM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: BGM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.69% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.48B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.46 | 52 Weeks Range 3.33 - 17.17 | Updated Date 06/16/2025 |
52 Weeks Range 3.33 - 17.17 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.32% | Operating Margin (TTM) -5.41% |
Management Effectiveness
Return on Assets (TTM) -3.84% | Return on Equity (TTM) -16.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2465318227 | Price to Sales(TTM) 83.14 |
Enterprise Value 2465318227 | Price to Sales(TTM) 83.14 | ||
Enterprise Value to Revenue 98.23 | Enterprise Value to EBITDA 2801.9 | Shares Outstanding 163960000 | Shares Floating 2832616 |
Shares Outstanding 163960000 | Shares Floating 2832616 | ||
Percent Insiders 7.29 | Percent Institutions - |
Upturn AI SWOT
Qilian International Holding Group Limited
Company Overview
History and Background
Qilian International Holding Group Limited (QLI) focuses on developing, manufacturing, and distributing pharmaceutical products, traditional Chinese medicine products, and dietary supplements. Founded and based in China, its history includes expansion and product diversification.
Core Business Areas
- Pharmaceutical Products: Production and distribution of various pharmaceutical products. Competitors include other Chinese pharmaceutical manufacturers.
- Traditional Chinese Medicine (TCM): Development and sale of TCM products. Faces competition from established TCM brands.
- Dietary Supplements: Manufacturing and distribution of dietary supplements. Competing with both domestic and international supplement brands.
Leadership and Structure
Information regarding the precise structure is not readily available. Typically, it would involve a board of directors, executive management, and operational divisions for manufacturing, sales, and research.
Top Products and Market Share
Key Offerings
- Product Name 1: Otc Drugs - The company offers various over-the-counter (OTC) drugs. Market share data not publicly available. Competitors include local and international OTC drug manufacturers.
- Product Name 2: TCM Products - TCM products form a significant portion of the revenue. Market share data not publicly available. Competitors include other established TCM brands in China.
- Product Name 3: Dietary Supplements - Sales of dietary supplements contribute to revenue. Market share data not publicly available. Competitors include domestic and international supplement manufacturers
Market Dynamics
Industry Overview
The Chinese pharmaceutical market is large and growing but highly competitive and regulated. The TCM market has a long history and remains significant. The dietary supplement market is also expanding due to increasing health awareness.
Positioning
Qilian International Holding Group Limited is a smaller player relative to the major pharmaceutical companies in China. Its competitive advantage may lie in niche markets or specific TCM products. The company is positioned to capture segments of China's TCM market.
Total Addressable Market (TAM)
The TAM for pharmaceuticals and TCM in China is estimated at hundreds of billions of dollars annually. QLI is a relatively small player. The company is competing for market share in these segments.
Upturn SWOT Analysis
Strengths
- Established presence in China
- Focus on TCM products
- Diversified product portfolio
Weaknesses
- Small market share relative to competitors
- Limited global reach
- Potential regulatory risks
Opportunities
- Growing demand for TCM products
- Expanding dietary supplement market
- Potential for international expansion
Threats
- Intense competition
- Stringent regulations
- Fluctuations in raw material prices
Competitors and Market Share
Key Competitors
Competitive Landscape
Competitive landscape analysis unavailable due to lack of data.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not readily available.
Future Projections: Future growth projections are not readily available due to the lack of recent financial data.
Recent Initiatives: Information on recent initiatives cannot be provided due to the limitations of accessing accurate and up-to-date information.
Summary
Qilian International Holding Group Limited is a smaller pharmaceutical company operating in China focusing on traditional medicines and dietary supplements. Reliable, recent financials are unavailable for a thorough analysis. The company faces intense competition. Its growth depends on its ability to navigate regulatory challenges and gain market share in a competitive landscape. More reliable financial information is needed to fully assess the company's situation.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Publicly available information
- SEC Filings
- Company website (if available)
Disclaimers:
The information provided is based on limited publicly available data and may not be entirely accurate or up-to-date. This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qilian International Holding Group Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-12 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 298 | Website https://www.bgm.ltd |
Full time employees 298 | Website https://www.bgm.ltd | ||
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.